Preview

Pharmacokinetics and Pharmacodynamics

Advanced search

Technological aspects of the production of orodispersible tablets

https://doi.org/10.37489/2587-7836-2026-2-90-100

EDN: FPTZJQ

Abstract

Development of the composition and manufacturing technology of orodispersible tablets (ODT) is becoming increasingly promising due to their applicability in pediatric and geriatric practice, including for patients with dysphagia or in the absence of water. Furthermore, the ability to ensure the absorption of the active pharmaceutical ingredient (API) through the oral mucosa, bypassing the gastrointestinal tract, opens up new opportunities for preventing the adverse effects of the acidic gastric environment and first-pass metabolism on the API. This article provides an overview of the principal methods and technologies for the production of ODT, featuring examples of the most advanced technologies, as well as the excipients employed.

About the Authors

S. V. Tishkov
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Sergey V. Tishkov – PhD, Cand. Sci. (Pharm.), Leading Researcher of the Laboratory of Drug Technology of the Department of Quality and Technology
of Drugs

Moscow



D. D. Vuynovich
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Danilo D. Vuynovich – Graduate Student, Leading Engineer of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs

Moscow



V. B. Markeev
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Vladimir B. Markeev – PhD, Cand. Sci. (Pharm.), Senior Researcher of the Laboratory of Drug Technology of the Department of Quality and Technology
of Drugs 

Moscow



V. L. Mistyukov
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Vladislav L. Mistyukov – Graduate Student, Leading Engineer of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs 

Moscow



M. S. Sergeeva
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Mariya S. Sergeeva – PhD, Cand. Sci. (Pharm.), Head of the Laboratory of Drug Standardization and Quality control of the Department of Quality and Technology of Drugs

Moscow



E. V. Blynskaya
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Evgenia V. Blynskaya – PhD, Dr. Sci. (Pharm.), Head of the Laboratory of Drug Technology of the Department of Quality and Technology of Drugs

Moscow



V. L. Dorofeev
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation

Vladimir L. Dorofeev – PhD, Dr. Sci. (Pharm), Professor, Acting General Director

Moscow



References

1. [Alekseyev KV, Blynskaya YeV, Sizyakov SA, et al. Excipients in the technology of modified-release tablets. Farmatsiya. 2009;(6):49-56. (In Russ.)].

2. [Blynskaya EV, Tishkov SV, Alekseev KV. Three-dimensional printing technology for the production of dosage forms. Drug development & registration. 2018;(3):10-19. (In Russ.)].

3. [Tishkov SV, Gavrilov DI, Alekseev KV, et al. Innovative technologies for the production of lyophilisate tablets and orally dispersible tablets. Izvestiya GGTU. Meditsina, farmatsiya. 2024;4(20):113-119. (In Russ.)]. doi: 10.51620/2687-1521-2024-4-20-113-119. EDN: HCTHCW

4. [Shevchenko AM, Kovalevskaya EG. Technological features of the development and production methods orodispersible tablets. Razrabotka i registratsiya lekarstvennykh sredstv. 2014;1(6):26-30. (In Russ.)]. EDN: SHBHQZ

5. Brown D. Orally disintegrating tablets-taste over speed. Drug Del Technol. 2003;3:58-61.

6. Deepak K. Orally disintegrating tablets. Tablets and Capsules. 2004;7:30-35.

7. Chandrasekhar R, Hassan Z, Alhusban F, et al. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm. 2009 May;72(1):119-29. doi: 10.1016/j.ejpb.2008.11.011.

8. Fukami J, Yonemochi E, Yoshihashi Y, Terada K. Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose. Int J Pharm. 2006 Mar 9;310(1-2):101-9. doi: 10.1016/j.ijpharm.2005.11.041.

9. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258-74. doi: 10.2174/187221108786241660.

10. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharmaceutical Technology. 2003;27(11):92-100.

11. Koizumi K, Watanabe Y, Morita K, et al. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997;152(1):127-131. doi: 10.1016/S0378-5173(97)04924-7.

12. Ghosh TK, Pfister WR. Quick-Dissolving Oral Dosage Forms: Scientific and Regulatory Considerations from a Clinical Pharmacology and Biopharmaceutics Perspective. In: Ghosh TK, Pfister WR, eds. Drug Delivery to the Oral Cavity: Molecules to Market. New York, NY: Marcel Dekker; 2005:337-356.

13. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release. 2005 Jun 20;105(1-2):16-22. doi: 10.1016/j.jconrel.2005.01.018.

14. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci. 2002 Apr;15(3):295-305. doi: 10.1016/s0928-0987(02)00011-8.

15. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998 Apr;50(4):375-82. doi: 10.1111/j.2042-7158.1998.tb06876.x.

16. Corveleyn S, Remon JP. Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int J Pharm. 1998;166(1):65-74. doi: 10.1016/S0378-5173(98)00024-6.

17. Dobetti L. Fast-melting tablets: Developments and technologies. Pharmaceutical Technology. 2001;(Suppl):44-50.

18. Bogner RH, Wilkosz MF. Fast-dissolving tablets: New dosage convenience for patients. US Pharmacist. 2002;27(3):34-43.

19. Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul. 2009 Jan;3(1):26-39. doi: 10.2174/187221109787158364.

20. Sasidhar RLC, Vidyadhara S, Maheswari GV, et al. Solubility and dissolution rate enhancement of olmesartan medoxomil by complexation and development of mouth dissolving tablets. Advan. Biol. Res. 2013;7(2):32-41. doi: 10.5829/idosi.abr.2013.7.2.7244.

21. Parkash V, Maan S, Deepika, Yadav SK, Hemlata, Jogpal V. Fast disintegrating tablets: Opportunity in drug delivery system. J Adv Pharm Technol Res. 2011 Oct;2(4):223-35. doi: 10.4103/2231-4040.90877.

22. Gohel M, Patel M, Amin A, et al. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004 Apr 26;5(3):e36. doi: 10.1208/pt050336.

23. Lee KJ, Kang A, Delfino JJ, et al. Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form. Drug Dev Ind Pharm. 2003 Oct;29(9):967-79. doi: 10.1081/ddc-120025454.


Review

For citations:


Tishkov S.V., Vuynovich D.D., Markeev V.B., Mistyukov V.L., Sergeeva M.S., Blynskaya E.V., Dorofeev V.L. Technological aspects of the production of orodispersible tablets. Pharmacokinetics and Pharmacodynamics. 2026;(2):90-100. (In Russ.) https://doi.org/10.37489/2587-7836-2026-2-90-100. EDN: FPTZJQ

Views: 47

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2587-7836 (Print)
ISSN 2686-8830 (Online)